뉴스벤징가
Johnson & Johnson Hits Target With IMAAVY In Rare Blood Disorder
· 발표
기사 요약
Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.
기사 원문에서 발췌했어요.뉴스 본문을 불러오고 있어요.
Johnson & Johnson reports Phase 2/3 data showing IMAAVY improved hemoglobin levels in wAIHA patients and secured FDA Priority Review.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…